Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | THPO | P40225 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | ACE | P12821 | 3/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.47 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.36 |
| ▸ | FNTB | P49356 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661780 | 1.00 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL9324856 | 1.00 | KDM4E (0.61) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL29476459 | 0.86 | MAPT (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL5060887 | 0.86 | MAPT (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL121965 | 0.86 | MAPT (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL930021 | 0.86 | MAPT (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| Bucillamine SCHEMBL522713 | 0.86 | MAPT (0.59) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL929062 | 0.84 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL929540 | 0.84 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL31234330 | 0.84 | KDM4E (0.57) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3473249-A1 | CROSSLINKABLE DENDRIMERS | Wayne State University (US) | 2019-04-24 | — | — | EP | claimed |
| EP-4688734-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | Lento Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4688734-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | Lento Bio, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260035345-A1 | N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260035345-A1 | N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2024243373-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024243373-A1 | CYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | LENTO BIO, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | WAYNE STATE UNIVERSITY (US) | 2022-09-20 | — | — | US | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084747-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| EP-0981507-B1 | PROCESS FOR THE REMOVAL OF HEAVY METALS | ZAMBON SPA (IT) | 2004-08-18 | — | — | EP | disclosed |
| US-6239301-B1 | USING A CYSTEINE DERIVATIVE | ZAMBON GROUP S.P.A. (IT) | 2001-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035345-A1 | N-PIVALOYLCYSTEINE DERIVATIVES FOR THE TREATMENT OF PRESBYOPIA | CRYAB, CRYAA, CRYZ | KDM4E 1882/4885MAPT 2090/4885THRB 3540/4885 |
| US-11446238-B2 | Injectable dendrimer hydrogel nanoparticles | PAM, UACA, FLT1 | KDM4E 3741/4885MAPT 2282/4885THRB 988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.